Zaleplon (Sonata®) analysis in postmortem specimens by gas chromatography-electron capture detection

Journal of Analytical Toxicology

Volumn 33, Issue 8, 2009, Pages 481-485

  Anderson, Daniel T ^a   Budd, Robert D ^a  

^a Los Angeles County Department of Coroner   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZALEPLON; ACETAMIDE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; PYRIMIDINE DERIVATIVE;

ARTICLE; AUTOPSY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ELECTRON CAPTURE DETECTION; GAS CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; ADULT; CASE REPORT; FEMALE; FORENSIC TOXICOLOGY; MALE; MASS FRAGMENTOGRAPHY; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SOLID PHASE EXTRACTION; SUBSTANCE ABUSE; TISSUE DISTRIBUTION; VALIDATION STUDY;

ACETAMIDES; ADULT; FEMALE; FORENSIC TOXICOLOGY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; SUBSTANCE ABUSE DETECTION; TISSUE DISTRIBUTION;

EID: 70350493486     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/33.8.481     Document Type: Article

References (12)

1. Placement of zaleplon into Schedule IV of the Controlled Substance Act. [Fed. Regist. 64(178): 49982-49983 (1999)] Microgram 32(11): 306 (1999).
2. http://sleep.emedtv.com/zaleplon/generic-zaleplon.html (accessed February 2009).
3. C.R. Rush, J.M. Frey, and R.R. Griffiths. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) 145(1): 39-51 (1999).
4. Thomson Micromedex® Healthcare Series (1974-2009).
5. B. Beer, J.R. Ieni, W.H. Wu, D. Clody, P. Amorusi, J. Rose, T. Mant, J. Gaudreault, A. Cato, and W. Stern. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. J. Clin. Pharmacol. 34(4): 335-344 (1994).
6. D.J. Greenblatt, J.S. Harmatz, L.L. von Moltke, B.L. Ehrenberg, L. Harrel, K. Corbett, M. Counihan, J.A. Graf, M. Darwish, P. Mertzanis, P.T. Martin, W.H. Cervallos, and R.I. Shader. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin. Pharmacol. Ther. 64(5): 553-561 (1998).
7. A.S. Rosen, P. Fournié, M. Darwish, P. Danjou, and S.M. Troy. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm. Drug Dispos. 20(3): 171-175 (1999).
8. R.C. Baselt. Disposition of Toxic Drugs and Chemicals in Man, 7th ed. Biomedical Publications, Foster City, CA, 2004, pp 1202-1203.
9. F. Feng, J. Jiang, H. Dai, and J.Wu. Development and validation of a high-performance liquid chromatography-electrospray ionization-mass spectrometry assay for the determination of zaleplon in human plasma. J. Chromatogr. Sci. 41: 17-21 (2003).
10. C. Giroud, M. Augsburger, A. Menetrey, and P. Mangin. Determination of zaleplon and zolpidem by liquid chromatography-turbo-ionspray mass spectrometry: application to forensic cases. J. Chromatogr. B 789: 131-138 (2003).
11. K.A. Moore, T.L. Zemrus, V. Ramcharitar, B. Levine, and D.R. Fowler. Mixed drug intoxication involving zaleplon ("Sonata"). Forensic Sci. Int. 1342: 120-122 (2003).
12. M.E. Stillwell. Zaleplon and driving impairment. J. Forensic Sci. 48: 677-679 (2003).